Halozyme Therapeutics HALO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's cash & equivalents?
- Halozyme Therapeutics (HALO) reported cash & equivalents of $312.01M in Q1 2026.
- How has Halozyme Therapeutics's cash & equivalents changed year-over-year?
- Halozyme Therapeutics's cash & equivalents increased by 76.9% year-over-year, from $176.33M to $312.01M.
- What is the long-term trend for Halozyme Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's cash & equivalents has grown at a -1.6% compound annual growth rate (CAGR), from $148.2M to $136.42M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and financial flexibility, while a significant decrease may indicate cash burn or heavy capital deployment.
- How does cash & equivalents compare across companies?
- Biotech companies typically maintain higher cash balances to fund long-term R&D and clinical trials compared to mature manufacturing firms.